IDERA PHARMACEUTICALS INC (IDRA) Stock Analyst Ratings
USA - NASDAQ:IDRA - US45168K4058 - Common Stock
0.425 USD
-0.12 (-21.57%)
0.42 USD
-0.01 (-1.18%)
ChartMill assigns a Buy % Consensus number of 43% to IDRA. The Buy consensus is the weighted average rating of the current analysts ratings.
IDRA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about IDRA.
In the previous month the buy percentage consensus was at a similar level.
IDRA was analyzed by 6 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-03-19 | JMP Securities | Downgrade | Outperform -> Market Perform |
| 2021-03-19 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2021-03-19 | Wedbush | Downgrade | Outperform -> Neutral |
| 2021-03-19 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-03-19 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
IDERA PHARMACEUTICALS INC / IDRA FAQ
What is the consensus rating for IDRA stock?
The consensus rating for IDERA PHARMACEUTICALS INC (IDRA) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
What is the number of analysts for IDRA stock?
The number of analysts covering IDERA PHARMACEUTICALS INC (IDRA) is 6.